Oren J Becher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9104193/publications.pdf

Version: 2024-02-01

83	6,342	126907	82547
papers	citations	33 h-index	72 g-index

87	87	87	8660
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma. Science, 2013, 340, 857-861.	12.6	1,074
2	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
3	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	28.4	469
4	PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes and Development, 2008, 22, 436-448.	5.9	413
5	Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathologica, 2014, 128, 573-581.	7.7	258
6	Reasons for Pediatrician Nonadherence to Asthma Guidelines. JAMA Pediatrics, 2001, 155, 1057.	3.0	249
7	Modeling Adult Gliomas Using RCAS/t-va Technology. Translational Oncology, 2009, 2, 89-IN6.	3.7	238
8	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	1.2	217
9	Genetically Engineered Models Have Advantages over Xenografts for Preclinical Studies. Cancer Research, 2006, 66, 3355-3359.	0.9	205
10	Sonic Hedgehog Pathway Activation Is Induced by Acute Brain Injury and Regulated by Injury-Related Inflammation. Journal of Neuroscience, 2009, 29, 10299-10308.	3.6	192
11	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell, 2020, 183, 1962-1985.e31.	28.9	177
12	Gli Activity Correlates with Tumor Grade in Platelet-Derived Growth Factorâ€“Induced Gliomas. Cancer Research, 2008, 68, 2241-2249.	0.9	160
13	Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma. Cancer Research, 2010, 70, 2548-2557.	0.9	149
14	PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma. PLoS ONE, 2013, 8, e77639.	2.5	136
15	Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. PLoS ONE, 2017, 12, e0169485.	2.5	130
16	Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG. Molecular Cancer Research, 2017, 15, 1243-1254.	3.4	120
17	Cancer stem cells and survival pathways. Cell Cycle, 2008, 7, 1371-1378.	2.6	108
18	The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nature Communications, 2019, 10, 2235.	12.8	96

#	Article	IF	Citations
19	ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nature Communications, 2019, 10, 1023.	12.8	87
20	Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatric Research, 2014, 75, 205-209.	2.3	70
21	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26409.	1.5	66
22	Reirradiation for recurrent medulloblastoma. Cancer, 2011, 117, 4977-4982.	4.1	65
23	Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma. PLoS ONE, 2011, 6, e14545.	2.5	64
24	A High-Throughput In Vitro Drug Screen in a Genetically Engineered Mouse Model of Diffuse Intrinsic Pontine Glioma Identifies BMS-754807 as a Promising Therapeutic Agent. PLoS ONE, 2015, 10, e0118926.	2.5	57
25	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2019, 25, 5572-5583.	7.0	52
26	ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-Bâ€“Driven Brainstem Glioma Model. Molecular Cancer Therapeutics, 2016, 15, 819-829.	4.1	49
27	Tumor location, but not H3.3K27M, significantly influences the bloodâ€“brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. Journal of Neuro-Oncology, 2016, 126, 243-251.	2.9	49
28	Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma. Brain, 2021, 144, 53-69.	7.6	43
29	Disease Control and Ototoxicity Using Intensity-Modulated Radiation Therapy Tumor-Bed Boost for Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, e15-e20.	0.8	42
30	Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro-Oncology, 2020, 22, 1302-1314.	1.2	42
31	A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: <scp>L</scp>ongâ€term progressionâ€free survival of patients with resistant neuroblastoma. International Journal of Cancer, 2017, 140, 480-484.	5.1	41
32	Heterozygosity for Pten Promotes Tumorigenesis in a Mouse Model of Medulloblastoma. PLoS ONE, 2010, 5, e10849.	2.5	40
33	A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells. Neoplasia, 2016, 18, 60-70.	5.3	40
34	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE, 2017, 12, e0178593.	2.5	38
35	Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2015, 5, 172.	2.8	36
36	<scp>A</scp>urora Kinase <scp>B</scp> Is a Potential Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma. Brain Pathology, 2013, 23, 244-253.	4.1	33

#	Article	IF	Citations
37	Diffuse Intrinsic Pontine Glioma. Journal of Child Neurology, 2016, 31, 1377-1385.	1.4	31
38	Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. Acta Neuropathologica Communications, 2019, 7, 64.	5.2	31
39	The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma. Oncotarget, 2015, 6, 12141-12155.	1.8	30
40	Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. Acta Neuropathologica Communications, 2014, 2, 134.	5.2	27
41	Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models. Journal of Clinical Investigation, 2021, 131, .	8.2	27
42	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). Pediatric Blood and Cancer, 2021, 68, e28879.	1.5	24
43	Tumour immune landscape of paediatric high-grade gliomas. Brain, 2021, 144, 2594-2609.	7.6	21
44	IGFBP2 Is Overexpressed by Pediatric Malignant Astrocytomas and Induces the Repair Enzyme DNA-PK. Journal of Child Neurology, 2008, 23, 1205-1213.	1.4	20
45	T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity. Child's Nervous System, 2018, 34, 449-455.	1.1	18
46	CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2018, 8, 191.	2.8	18
47	Magnetic Resonance Imaging-Guided Focused Ultrasound-Based Delivery of Radiolabeled Copper Nanoclusters to Diffuse Intrinsic Pontine Glioma. ACS Applied Nano Materials, 2020, 3, 11129-11134.	5.0	17
48	Splicing is an alternate oncogenic pathway activation mechanism in glioma. Nature Communications, 2022, 13, 588.	12.8	17
49	Large Congenital Melanotic Nevi in an Extremity with Neurocutaneous Melanocytosis. Pediatric Dermatology, 2009, 26, 79-82.	0.9	16
50	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Research, 2019, 79, 4026-4041.	0.9	16
51	A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cellâ€ofâ€origin dependent effects of <scp>H3K27M</scp>. Glia, 2022, 70, 1681-1698.	4.9	15
52	Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. Neuro-Oncology, 2020, 22, 195-206.	1.2	14
53	Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. JCI Insight, 2022, 7, .	5.0	14
54	Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma. Neuro-Oncology, 2021, 23, 1348-1359.	1.2	12

#	Article	IF	Citations
55	Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma. Neurosurgery, 2020, 87, E680-E688.	1.1	11
56	A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis. Acta Neuropathologica Communications, 2022, 10, 47.	5.2	11
57	Sox2, a marker for stemâ€like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. EMBO Journal, 2014, 33, 1984-1986.	7.8	10
58	For pediatric glioma, leave no histone unturned. Science, 2014, 346, 1458-1459.	12.6	9
59	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget, 2015, 6, 11751-11767.	1.8	9
60	Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget, 2017, 8, 9366-9374.	1.8	9
61	Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neuro-Oncology Advances, 2019, 1, vdz004.	0.7	8
62	ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma. Neurosurgery, 2020, 86, 742-751.	1.1	8
63	Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 771-779.	0.8	7
64	Evidence for and against regional differences in neural stem and progenitor cells of the CNS. Genes and Development, 2010, 24, 2233-2238.	5.9	6
65	Prenatal overexpression of plateletâ€derived growth factor receptor A results in central nervous system hypomyelination. Brain and Behavior, 2021, 11, e2332.	2.2	5
66	HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma. Neuro-Oncology, 2019, 21, 1091-1092.	1.2	4
67	CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?. EBioMedicine, 2019, 44, 16-17.	6.1	4
68	Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas. Neuro-Oncology, 2023, 25, 97-107.	1.2	3
69	Genetics of glioma. , 0, , 1-23.		1
70	PDTM-43. THE ROLE OF TUMOR ASSOCIATED MACROPHAGES IN PEDIATRIC HIGH-GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi213-vi213.	1.2	1
71	DIPG-68. ALPHA-THALASSEMIA X-LINKED MENTAL RETARDATION PROTEIN (ATRX) LOSS-OF-FUNCTION IN A MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii300-iii300.	1.2	1
72	ET-06 * PRECLINICAL TESTING OF THE HISTONE DEACETYLASE INHIBITOR, PANOBINOSTAT, IN A GENETICALLY ENGINEERED DIFFUSE INTRINSIC PONTINE GLIOMA MOUSE MODEL. Neuro-Oncology, 2014, 16, v80-v80.	1.2	0

#	Article	IF	Citations
73	Glioma Stem-like Cells Keep Their H3.3 Variant Levels at Bay. Cancer Cell, 2015, 28, 679-680.	16.8	0
74	Pediatric High-Grade Gliomas and DIPG. Molecular Pathology Library, 2015, , 95-104.	0.1	0
75	HG-63NOVEL DISSOCIATIVE STEROIDS FOR TREATMENT OF EDEMA IN CHILDHOOD INTRACRANIAL BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii62.2-iii62.	1.2	0
76	PDTB-17. PRE-CLINICAL EVALUATION OF TRAMETINIB IN AÂGENETICALLY ENGINEERED MOUSE MODEL OF DIPG. Neuro-Oncology, 2016, 18, vi153-vi153.	1.2	0
77	PDTM-16. AN IMPROVED DIFFUSE INTRINSIC PONTINE GLIOMA MODEL INITIATED IN OLIG2-EXPRESSING PROGENITORS OF THE NEONATAL BRAINSTEM. Neuro-Oncology, 2018, 20, vi207-vi207.	1.2	0
78	PDTM-12. DLX2 TRANSCRIPTIONAL REGULATION OF CENTRAL NERVOUS SYSTEM CELL FATE RELEVANCE TO PEDIATRIC DIFFUSE MIDLINE GLIOMAS WITH HISTONE 3 MUTATIONS. Neuro-Oncology, 2018, 20, vi206-vi206.	1.2	0
79	GENE-06. THE ONCOHISTONE H3.3K27M DRIVES DIFFUSE INTRINSIC PONTINE GLIOMA INDEPENDENT OF FUNCTIONAL EZH2. Neuro-Oncology, 2018, 20, vi103-vi104.	1.2	0
80	IMMU-06. DELTA-24-RGD EXPRESSING POSITIVE IMMUNE MODULATORS SHOW ANTI-DIPG EFFECT AND INCREASE TUMOR IMMUNE INFILTRATION. Neuro-Oncology, 2021, 23, i28-i28.	1.2	0
81	DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii285-iii286.	1.2	0
82	EXTH-63. A NOVEL MOUSE MODEL OF DIFFUSE MIDLINE GLIOMA FOR TARGETED IMMUNOTHERAPY. Neuro-Oncology, 2021, 23, vi177-vi177.	1.2	0
83	EXTH-67. PHARMACOLOGIC INHIBITION OF LYSINE SPECIFIC DEMETHYLASE-1 (LSD1) AS AN ADJUVANT IMMUNE-SENSITIZATION STRATEGY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2020, 22, ii102-ii102.	1.2	0